International Conference & Exhibition on Cancer Science & Therapy

15-17 August 2011 Las Vegas, USA

Dr. Michael Mingzhao Xing

Johns Hopkins University School of Medicine, USA

Keynote: J Cancer Sci Ther

Abstract :

Dr.Mingzhao Xing, M.D., Ph.D., is Associate Professor of Medicine, Oncology and Cellular and Molecular Medicine, Co-Director of the Thyroid Tumor Center, and Chief of the Laboratory for Cellular and Molecular Thyroid Research at the Johns Hopkins University School of Medicine. Following his initial medical training at the Second Military Medical University in Shanghai, China, he obtained a Ph. D. degree in Physiology and Biophysics at Case Western Reserve University in Cleveland. He subsequently completed an internal medicine residency at the Greater Baltimore Medical Center and a clinical fellowship in Endocrinology and Metabolism at the Johns Hopkins University School of Medicine. Upon completing the fellowship, Dr. Xing was recruited to the faculty at the Division of Endocrinology and Metabolism of the Johns Hopkins Hospital. Dr. Xing serves on a number of national and international professional committees/panels, including, for example, National Institute of Health study sections, American Thyroid Association committees, several cancer research grant review panels in European counties. He also serves as a member or editor on a number of subspecialty journals, such as Journal of Clinical Endocrinology and Metabolism, Endocrine-Related Cancer, and Thyroid. Dr. Xing practices clinical endocrinology as a subspecialty consultant and teaching attending at the Johns Hopkins Hospital while also conducting laboratory research as a physician scientist. His main clinical and research interest is in thyroid diseases, particularly thyroid tumors. Supported by the American Cancer Society and NIH R0-1 grants, his laboratory has been studying molecular, genetic and epigenetic mechanisms of thyroid cancer and their clinical translations. His team has published actively in these areas, particularly in relation to the MAP kinase and PI3K/Akt pathways. He is coholder of a patent on the initial discovery and clinical characterization of the BRAF mutation in thyroid cancer. He has published more than 80 scientific articles. Among his professional recognitions/ awards are the US FAMRI Clinical Innovator Award, Maryland Innovator Award, American Cancer Society RSG Award, and â�?�?Americaâ�?�?s Top Physicianâ�? recognition.